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Introduction
Pompe disease is a rare, progressive, often fatal metabolic
myopathy, which manifests as a clinical spectrum that
varies with respect to age at onset, rate of disease progres-
sion, and extent of organ involvement. The underlying
pathology is deficiency of acid alpha-glucosidase (GAA).
To gain a better understanding of Pompe disease, a global,
voluntary, observational Registry was developed to collect
anonymous, longitudinal data.
Preliminary data overview
As of March 2008, 494 patients from 23 countries were
enrolled; the majority (72%) Caucasian. Europe and
North America enroll 87% of patients. Median age of
infants at symptom onset was 2.0 months (n = 94) and at
diagnosis was 4.0 months (n = 93). Median age of adults
at symptom onset was 27.7 years (n = 293) and at diagno-
sis was 35.3 years (n = 289). Symptoms most frequently
reported by patients ≥ 18 years old (n = 321) include:
muscle weakness [lower extremities (80%), upper extrem-
ities (69%), trunk (53%)]; shortness of breath after exer-
cise (61%) and at rest (31%); dependence on respiratory
support (38%); sleep disturbance/apnea (35%); orthop-
nea (32%); and scapular winging (31%). Approximately
half of patients genotyped expressed the IVS1-13T>>G
mutation.
Summary
These results show significant delay from symptom onset
to diagnosis in adult patients, highlighting the need for
greater disease awareness. Registry data on prevalence and
age at onset of symptoms may allow earlier patient iden-
tification, enabling intervention before irreversible mus-
cle damage occurs. Analysis of registry data over time may
increase understanding of the evolution of, and interac-
tion between, impairments and function under varying
conditions and interventions, allowing improved clinical
management.
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